The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.

The prognostic significance of residual nodal disease in otherwise complete pathologic responders (ypT0N+) to neoadjuvant chemoradiation (nCRT) for esophageal cancer is unknown. ypT0N+ responders were identified from a single institution database of esophageal cancer patients undergoing esophagectomy and were compared to patients without locoregional disease (ypT0N0) and to non-complete responders (ypT+). Out of 487 patients, 196 ypT0N0 and 14 ypT0N+ patients were identified. Pre-treatment stage was similar between ypT0N0 and ypT0N+ patients: 66% versus 73% of patients had uT3 disease (P = 0.50) and 76% versus 55% had nodal involvement (P = 0.49), respectively. Locoregional recurrence (43%) was more common in ypT0N+ patients. Median overall survival (OS) was worse in ypT0N+ patients (14.8 months) compared to ypT0N0 patients (92.2 months) and ypT+ patients (38.0 months, P < 0.001). Median OS of ypT0N+ patients was similar to ypT+ stage II (29.6 months, P = 0.84) and stage III (27.5 months, P = 0.95) disease. No difference in median OS existed in patients with residual nodal disease (n = 163) based on local response (14.8 months in ypT0N+ and 22.5 months in ypT+N+ patients, P = 0.55). Residual nodal disease in esophageal cancer patients with complete response in the primary tumor following nCRT portends a poor prognosis and behaves similar to pathologic stage II/III disease.

Blackham AU ，Yue B ，Almhanna K ，Saeed N ，Fontaine JP ，Hoffe S ，Shridhar R ，Frakes J ，Coppola D ，Pimiento JM ... -  《-》

Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.

Cho HJ ，Kim YH ，Kim HR ，Kim DK ，Park SI ，Kim JH ，Kim SB ... -  《-》

Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.

Shridhar R ，Hoffe SE ，Almhanna K ，Weber JM ，Chuong MD ，Karl RC ，Meredith K ... -  《-》

ypT0N+: the unusual patient with pathological complete tumor response but with residual lymph node disease after neoadjuvant chemoradiation for esophageal cancer, what's up?

Depypere LP ，Vervloet G ，Lerut T ，Moons J ，De Hertogh G ，Sagaert X ，Coosemans W ，Van Veer H ，Nafteux PR ... -  《-》

Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.

Burt BM ，Groth SS ，Sada YH ，Farjah F ，Cornwell L ，Sugarbaker DJ ，Massarweh NN ... -  《-》